Sector › Medicine

Press Releases

CNNが人々の生活をつなぐ医療の未来を探る特別番組「Tomorrow Transformed」を放送

Oct 04, 2024 19:00 JST

エーザイ、サウジアラビアの医薬品販売子会社が事業活動を開始

Oct 02, 2024 11:00 JST

Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia

Oct 02, 2024 10:28 HKT/SGT

Olympus Launches VISERA S, a New Imaging Platform

Sep 30, 2024 14:00 HKT/SGT

GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis

Sep 25, 2024 21:00 HKT/SGT

China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

Sep 24, 2024 22:00 JST

康哲藥業：磷酸蘆可替尼乳膏（白癜風）中國上市許可申請已獲受理

Sep 24, 2024 21:46 HKT/SGT

DEXIS Digital Ecosystem Expands With Three New Innovations To Streamline and Connect Dental Workflows

Sep 24, 2024 21:30 HKT/SGT

康哲药业：磷酸芦可替尼乳膏（白癜风）中国上市许可申请已获受理

Sep 24, 2024 21:20 HKT/SGT

China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China

Sep 24, 2024 21:00 HKT/SGT

Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表

Sep 24, 2024 18:00 JST

Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis

Sep 24, 2024 15:06 HKT/SGT

Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements

Sep 24, 2024 14:01 HKT/SGT

Olympus Launches New 4K Camera Head for Urological Endoscopy

Sep 20, 2024 14:00 HKT/SGT

Ainos、治療法が限られている希少疾患であるシェーグレン症候群の治療薬VELDONAの台湾での臨床試験開始計画を発表

Sep 19, 2024 21:00 JST

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Sep 17, 2024 20:30 HKT/SGT

君聖泰醫藥亮相香港國際生物科技論壇

Sep 17, 2024 15:00 HKT/SGT

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Sep 17, 2024 13:30 HKT/SGT

LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

Sep 17, 2024 09:08 HKT/SGT

君聖泰醫藥亮相香港國際生物科技論壇

Sep 16, 2024 14:53 HKT/SGT